Screener
Vaxcyte, Inc. PCVX Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (345,850) | (180,793) |
| Other income, net: | ||
| Interest income | 26,610 | 32,935 |
| Other income (expense) | (1,382) | 7,140 |
| Total other income, net | 25,228 | 40,075 |
| Net loss | $(320,622) | $(140,718) |
| Net loss per share, basic and diluted | $(2.30) | $(1.04) |
| Weighted-average shares outstanding, basic and diluted | 139,506,680 | 135,690,949 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s other income (expense)?
- Vaxcyte, Inc. (PCVX) reported other income (expense) of $25.23M in Q1 2026.
- How has Vaxcyte, Inc.'s other income (expense) changed year-over-year?
- Vaxcyte, Inc.'s other income (expense) decreased by 37.0% year-over-year, from $40.08M to $25.23M.
- What is the long-term trend for Vaxcyte, Inc.'s other income (expense)?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s other income (expense) has grown at a 157.1% compound annual growth rate (CAGR), from $3.59M to $157.05M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Vaxcyte, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude